Johnson & Johnson (NYSE:JNJ) Shares Purchased by Atria Wealth Solutions Inc.

Atria Wealth Solutions Inc. boosted its holdings in Johnson & Johnson (NYSE:JNJ - Free Report) by 1.7% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 162,782 shares of the company's stock after buying an additional 2,784 shares during the quarter. Atria Wealth Solutions Inc.'s holdings in Johnson & Johnson were worth $23,542,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently made changes to their positions in JNJ. IFS Advisors LLC lifted its stake in Johnson & Johnson by 138.9% in the fourth quarter. IFS Advisors LLC now owns 172 shares of the company's stock valued at $25,000 after buying an additional 100 shares during the period. Highline Wealth Partners LLC acquired a new position in shares of Johnson & Johnson during the third quarter worth approximately $31,000. Bay Harbor Wealth Management LLC bought a new stake in Johnson & Johnson during the fourth quarter worth $32,000. RPg Family Wealth Advisory LLC bought a new stake in Johnson & Johnson during the third quarter worth $35,000. Finally, Mowery & Schoenfeld Wealth Management LLC grew its stake in Johnson & Johnson by 58.7% in the 3rd quarter. Mowery & Schoenfeld Wealth Management LLC now owns 246 shares of the company's stock valued at $40,000 after purchasing an additional 91 shares during the period. 69.55% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

JNJ has been the subject of a number of recent analyst reports. Bank of America reduced their price objective on Johnson & Johnson from $160.00 to $159.00 and set a "neutral" rating for the company in a research note on Thursday, January 23rd. StockNews.com raised Johnson & Johnson from a "buy" rating to a "strong-buy" rating in a report on Saturday, January 25th. Royal Bank of Canada reaffirmed an "outperform" rating and issued a $181.00 price target on shares of Johnson & Johnson in a report on Wednesday. Stifel Nicolaus reduced their price objective on Johnson & Johnson from $170.00 to $155.00 and set a "hold" rating on the stock in a research report on Thursday, January 23rd. Finally, Argus upgraded Johnson & Johnson to a "strong-buy" rating in a research report on Friday, January 24th. Nine investment analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have assigned a strong buy rating to the company's stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $170.67.

Johnson & Johnson Stock Performance

JNJ stock traded up $2.67 during midday trading on Friday, reaching $162.35. The stock had a trading volume of 12,540,171 shares, compared to its average volume of 9,073,381. The stock has a market cap of $390.87 billion, a PE ratio of 24.41, a P/E/G ratio of 2.53 and a beta of 0.52. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.86 and a current ratio of 1.11. The firm has a fifty day simple moving average of $148.61 and a two-hundred day simple moving average of $155.89. Johnson & Johnson has a 52-week low of $140.68 and a 52-week high of $168.85.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its quarterly earnings results on Wednesday, January 22nd. The company reported $2.04 earnings per share for the quarter, topping the consensus estimate of $1.99 by $0.05. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. The company had revenue of $22.52 billion for the quarter, compared to the consensus estimate of $22.44 billion. During the same period last year, the firm earned $2.29 EPS. The firm's revenue for the quarter was up 5.3% compared to the same quarter last year. As a group, equities research analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 4th. Investors of record on Tuesday, February 18th will be issued a $1.24 dividend. This represents a $4.96 annualized dividend and a yield of 3.06%. The ex-dividend date is Tuesday, February 18th. Johnson & Johnson's payout ratio is 74.59%.

Insider Buying and Selling

In other news, Director Mark A. Weinberger acquired 1,000 shares of the stock in a transaction that occurred on Thursday, December 12th. The shares were bought at an average cost of $147.22 per share, for a total transaction of $147,220.00. Following the acquisition, the director now owns 1,000 shares in the company, valued at approximately $147,220. This represents a ∞ increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Timothy Schmid sold 403 shares of Johnson & Johnson stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $156.15, for a total transaction of $62,928.45. Following the sale, the executive vice president now directly owns 15,098 shares in the company, valued at approximately $2,357,552.70. The trade was a 2.60 % decrease in their position. The disclosure for this sale can be found here. 0.16% of the stock is currently owned by insiders.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.